Greenwich LifeSciences (NASDAQ: GLSI) CEO buys 1,800 shares stock

Rhea-AI Filing Summary

Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel, who is also a 10% owner, reported buying additional company stock. On January 13, 2026, he purchased 1,800 shares of common stock at a price of $29.83 per share. Following this open-market purchase, he beneficially owns 5,604,102 common shares, held in direct ownership.

Insider Trade Summary

Net Buyer: 1,800 shares ($53,694)

Net Buy 1 txn

Insider Patel Snehal

Role CEO and CFO

Bought 1,800 shs ($54K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,800	$29.83	$54K

Holdings After Transaction: Common Stock — 5,604,102 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/15/2026 - 06:05 AM Learn about SEC filing dates

FAQ

What insider transaction did GLSIs Snehal Patel report?

Snehal Patel reported an open-market purchase of 1,800 shares of Greenwich LifeSciences, Inc. common stock.

On what date did the GLSI insider stock purchase occur?

The reported transaction took place on January 13, 2026.

What price did the GLSI insider pay per share in this Form 4?

The shares were purchased at a price of $29.83 per share of common stock.

How many Greenwich LifeSciences (GLSI) shares does Snehal Patel own after the transaction?

After the reported transaction, Snehal Patel beneficially owns 5,604,102 shares of Greenwich LifeSciences common stock.

What is Snehal Patels role and relationship to Greenwich LifeSciences (GLSI)?

Snehal Patel is a director, the companys CEO and CFO, and a reported 10% owner of Greenwich LifeSciences, Inc.

Is the GLSI insider ownership reported as direct or indirect?

The 5,604,102 shares reported after the transaction are held in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Snehal

(Last) (First) (Middle)

C/O GREENWICH LIFESCIENCES, INC.

3992 BLUEBONNET DR., BUILDING 14

(Street)

STAFFORD TX 77477

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [ GLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		P		1,800	A	$29.83	5,604,102	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Snehal Patel	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.